Molecular Partners today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“In an environment where so many biotechs are looking for a quick exit to please their investors, it’s refreshing to see a company working to lay down roots and stick around for the long haul,” says Damian Garde, editor of FierceBiotech. “And Molecular Partners is going about it practically, doubling down on a validated platform as it expands its pipeline.”
Molecular Partners is a clinical-stage biopharmaceutical company developing DARPins™, a new class of small protein therapies with the potential to significantly improve the management of serious diseases, including cancer and sight-threatening disorders. DARPins™ are potent, specific and versatile therapies that are designed to function as a team to inhibit multiple disease-specific targets.
“We are honored that FierceBiotech has recognized Molecular Partners as one of the top biopharmaceutical companies worldwide,” said Christian Zahnd, PhD, Chief Executive Officer of Molecular Partners. “This distinction is especially meaningful as we rapidly advance our robust pipeline of DARPin™ therapies, which has been validated through our partnerships with industry leaders. DARPins™ can allow us access to a field of drug discovery with significant potential for improving the health of patients, the idea that drives every decision we make.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. Every year, FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. This is FierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at:Download the PDF